FOLFOX辅助化疗方案治疗早期结肠癌的疗效分析  

Analysis of the Efficacy of FOLFOX Adjuvant Chemotherapy Regimen for the Treatment of Early Colon Cancer

作　　者：谭亭昭 TAN Tingzhao(Department of Oncology,Liaocheng Infectious Diseases Hospital,Liaocheng 252000,Shandong,China)

机构地区：[1]聊城市传染病医院肿瘤科,山东聊城252000

出　　处：《中外医疗》2024年第21期90-93,共4页China & Foreign Medical Treatment

摘　　要：目的分析早期结肠癌使用FOLFOX辅助化疗方案的临床疗效。方法方便选取2020年4月—2022年10月聊城市传染病医院收治的80例早期结肠癌患者为研究对象,依照不同化疗方法分为对照组和观察组,各40例。两组均予以腹腔镜根治术治疗,对照组在术后采取常规化疗方案,观察组在术后则采取FOLFOX辅助化疗方案,比较两组的疗效、T细胞亚群水平、不良反应发生情况。结果观察组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(χ^(2)=4.500,P<0.05)。观察组治疗后辅助性T淋巴细胞(cluster of differentiation 4^(+),CD4^(+))、辅助性T淋巴细胞(cluster of differentiation 4^(+),CD4^(+))/抑制/杀伤性T淋巴细胞(cluster of differentiation 8^(+),CD8^(+))高于对照组,CD8^(+)低于对照组,差异有统计学意义(P均<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采用FOLFOX辅助化疗方案治疗早期结肠癌患者,有助于提高临床疗效,改善T细胞亚群,同时其不良反应发生率更低,安全性相对更高。Objective To analyze the clinical effect of FOLFOX adjuvant chemotherapy in the treatment of early colon cancer.Methods 80 patients with early colon cancer admitted to Liaocheng Infectious Disease Hospital from April 2020 to October 2022 were conveniently selected as the study objects,and were divided into control group and observation group according to different chemotherapy methods,with 40 cases in each group.Both groups were treated with laparoscopic radical surgery,the control group was treated with conventional chemotherapy after surgery,and the observation group was treated with FOLFOX adjuvant chemotherapy after surgery.The levels of efficacy,T cell subsets and state of incidence of adverse reactions were compared between the two groups.Results The total clinical efficacy of the observation group was 92.50%(37/40),which was higher than 75.00%(30/40)of the control group,the difference was statistically significant(χ^(2)=4.500,P<0.05).After treatment,helper lymphocyte T(cluster of differentiation 4^(+),CD4^(+))and CD4^(+)/inhibition/killer T lymphocytes(cluster of differentiation 8^(+),CD8^(+))in observation group were higher than control group,and CD8^(+)was lower than control group,the differences were statistically significant(all P<0.05).The total incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion FOLFOX adjuvant chemotherapy in the treatment of early colon cancer patients is helpful to improve clinical efficacy,improve T cell subsets,and the incidence of adverse reactions is lower,and the safety is relatively higher.

关 键 词：早期结肠癌 FOLFOX辅助化疗方案 临床疗效 T细胞亚群 

分 类 号：R73[医药卫生—肿瘤]